phthalimidomethyl propylamidine

Phthalimidomethyl propylamidine, also known as PMPA (not to be confused with the antiretroviral Tenofovir), is a potent and highly selective inhibitor of inducible nitric oxide synthase (iNOS). Developed primarily as a research tool and preclinical candidate by Glaxo Wellcome (now GSK), the compound belongs to the N-benzylamidine class of iNOS inhibitors. It works by competitively inhibiting the enzyme iNOS, which is responsible for the production of nitric oxide (NO) during inflammatory responses. By reducing NO levels, PMPA was investigated for its potential in treating conditions characterized by iNOS overactivity, such as septic shock, rheumatoid arthritis, and other inflammatory disorders. Although it demonstrated significant selectivity for iNOS over other isoforms (nNOS and eNOS) in preclinical models, it has primarily remained a laboratory reagent used to study the role of nitric oxide in disease pathology.

Other names

N-(3-(phthalimidomethyl)benzyl)propylamidineN-(3-(phthalimidomethyl)benzyl)propanimidamideN-(3-(phthalimidomethyl)benzyl)butyramidine